United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
United Therapeutics' board authorized a new share repurchase program of up to $2 billion, available through October 21, 2027. The company may execute via accelerated share repurchases, open market, or privately negotiated transactions, with no minimum purchase obligation and discretion to suspend at any time.
Key figures
- Deal Value Usd
- 2000000000
- Authorization expiry
- October 21, 2027
- Ongoing asr termination
- Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.